Parallels in Development of Monoclonal Antibodies and Therapeutic Vaccines Prompt Industry Optimism

Although the therapeutic vaccine market has experienced a range of setbacks and disappointments, technological evolution should ultimately enable therapeutic vaccines to make similar commercial breakthroughs as monoclonal antibodies, notes Kalorama.
 
 
Spread the Word
Listed Under

Tags:
Health
Medical
Healthcare
Physician
Doctor
Clinics
Hospital
Vaccines
Antibodies
Monoclonal
Cancer
Science

Industrys:
Medical
Health
Biotech

Location:
New York City - New York - US

Oct. 25, 2010 - PRLog -- For anyone thinking the idea of vaccines for cancer too fantastic to make a viable market, healthcare market research publisher Kalorama Information suggests a look at the history of another drug category – monoclonal antibodies.  Parallels between the emerging therapeutic vaccines industry and the history of the monoclonal antibodies industry can be seen, according to Kalorama. In the case of monoclonal antibodies, their eventual long-awaited success was driven by technology evolution from murine to chimeric, and ultimately humanized and fully human antibodies. Now the industry has exceeded $10 billion in annual sales, and is expected to continue to grow rapidly.

“At the time, not everyone thought mAbs would be accepted,” said Melissa Elder, analyst for Kalorama Information.  “Now they are thriving.’

As covered in their report, Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition, although the therapeutic vaccine market has experienced a range of setbacks and disappointments, technological evolution should ultimately enable therapeutic vaccines to make similar commercial breakthroughs as monoclonal antibodies. Scientists may be able to develop improved vaccines from a more complete understanding of the interactions between the immune system and cancer cells.

A new wave of 'off-the-shelf' generalized vaccines driven by genomic advances promise to remedy the commercial drawbacks of early personalized vaccines. As clinical experience mounts, new antigen delivery technologies appear and combination vaccines gain favor, the prospect of new non-toxic therapies for cancer and HIV gets closer to being reality.    

More information on cancer vaccines, including potential products and forecasts for each category of cancer, can be found at: http://www.kaloramainformation.com/Emerging-Cancer-Vaccin....

# # #

About Kalorama Information
Kalorama Information (www.kaloramainformation.com) supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter: www.twitter.com/KaloramaInfo.

Please direct all media inquiries to:
Andrea Hiller
Marketing Manager
(212) 807-2673
press@kaloramainformation.com
www.kaloramaInformation.com
End
Source:
Email:***@kaloramainformation.com Email Verified
Phone:(212) 807-2673
Zip:10016
Tags:Health, Medical, Healthcare, Physician, Doctor, Clinics, Hospital, Vaccines, Antibodies, Monoclonal, Cancer, Science
Industry:Medical, Health, Biotech
Location:New York City - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Oct 12, 2011
Kalorama Information PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share